Dental Caries and GLP-1: A Growing Concern
The rise of glucagon-like peptide-1 (GLP-1) receptor agonists, a type of medication used to treat type 2 diabetes and obesity, has brought a growing concern in the dental community. These medications, commonly prescribed drugs like Ozempic, have been linked to an increased risk of dental caries, a condition characterized by the breakdown of teeth due to acids produced by bacteria.
Understanding the Link between GLP-1 and Dental Caries
While the exact mechanism behind the link between GLP-1 and dental caries is not fully understood, research suggests that these medications can affect saliva production, which plays a crucial role in buffering acids and washing away bacteria. Reduced salivary flow can lead to an increased risk of dental caries, gum inflammation, and oral infections. Additionally, nausea and occasional vomiting associated with GLP-1 therapy can expose teeth to gastric acid, contributing to enamel erosion over time.
Oral Health Risks Associated with GLP-1 Medications
- Xerostomia (dry mouth) and halitosis (bad breath)
- Increased caries risk due to altered eating habits and reduced hydration
- Enamel erosion caused by exposure to gastric acid
- Tooth decay, sensitivity, and loss
- Impaired GLP-1 signaling, exacerbating glucotoxicity and lipotoxicity in individuals with diabetes or obesity
What Can You Do to Protect Your Dental Health?

If you're taking GLP-1 medications, it's essential to take steps to protect your dental health. This includes:
- Staying hydrated to reduce the risk of xerostomia and halitosis
- Maintaining good oral hygiene practices, such as regular brushing and flossing
- Attending regular dental check-ups to monitor your oral health
- Avoiding sugary and acidic foods and drinks that can contribute to dental caries
- Informing your dentist about your GLP-1 medication use to discuss potential dental implications
The Importance of Dialogue between Dentists and Prescribers
As the use of GLP-1 medications continues to rise, it's crucial for dentists and prescribers to have open dialogue about the potential oral health implications of these medications. By working together, we can develop effective prevention and treatment strategies to mitigate the risks associated with GLP-1 therapy.
Conclusion
The relationship between GLP-1 medications and dental caries is a growing concern that requires attention from both the dental and medical communities. By understanding the risks associated with these medications and taking preventative measures, we can help protect the oral health of individuals taking GLP-1 medications and ensure that they receive the best possible care.